Eli Lilly, Merck, Pfizer, Purdue University, and The Noramco Group are among the stakeholders looking to help address shortages in the U.S. injectable supply chain.
CEO Greg Behar said recent investments and partnerships have significantly expanded the global CDMO’s capacity in key areas such as pre-filled syringes and lyophilization.
Plant 5 will be operational in April and the CDMO is moving forward with plans for the construction of Plant 6 to “maintain the world’s No. 1 manufacturing capacity.”
Part of Vetter’s Center for Visual Inspection and Logistics, construction of the 22,500-square-meter extension began in late 2024, with completion expected by 2028.
